Collegeville, PA, United States of America

Jin Zeng


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jin Zeng

Introduction

Jin Zeng is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases involved in various diseases. His work exemplifies the intersection of scientific research and practical application in medicine.

Latest Patents

Jin Zeng holds a patent for "Thiazolopyrimidinone derivatives as PI3 kinase inhibitors." This invention relates to novel compounds that are useful for modulating the activity of the phosphoinositide 3' OH kinase family, specifically targeting PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. His innovative approach in this area has the potential to impact therapeutic strategies for diseases linked to these kinases.

Career Highlights

Jin Zeng is currently employed at GlaxoSmithKline LLC, where he continues to advance his research and development efforts. His work has led to the creation of valuable intellectual property that contributes to the company's portfolio in the pharmaceutical industry. With 1 patent to his name, he is recognized for his expertise and innovative thinking.

Collaborations

Throughout his career, Jin Zeng has collaborated with talented colleagues, including Hong Lin and Juan I Luengo. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to groundbreaking discoveries.

Conclusion

Jin Zeng's contributions to the field of pharmaceuticals through his innovative inventions and collaborations highlight the importance of research in developing new therapeutic options. His work continues to inspire advancements in medical science and showcases the impact of dedicated inventors in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…